Abstract: Provided is a detergent composition that contains (A) 2-17.5 mass % of an anionic surfactant, (B) 1-17.5 mass % of an amphoteric surfactant, (C) 2.5-17 mass % of a hydrophilic non-ionic surfactant and (D) 0.2-5 mass % of an oily component. However, the detergent composition does not contain substantial amounts of fatty acid monoglycerol esters and fatty acid monoalkyl monoglyceryl ethers having alkyl groups or acyl groups having 9 or more carbon atoms. The detergent composition does not contain substantial amounts of fatty acid diglycerol esters or fatty acid monoalkyl diglyceryl ethers which have alkyl groups or acyl groups having 8 or more carbon atoms.
Abstract: Software and lasers are used in finishing apparel to produce a desired wear pattern or other design. A technique includes determining a fabric's response to a laser, capturing an initial image of a wear pattern on a garment, and processing the initial image to obtain a working image in grayscale. The working image is further processed to obtain a difference image by comparing each pixel relative to a dark reference. The difference image is converted to a laser values image by using the previously determined fabric response to the laser.
Type:
Grant
Filed:
August 21, 2017
Date of Patent:
October 25, 2022
Assignee:
Levi Strauss & Co.
Inventors:
Jennifer Schultz, James Barton Sights, Christopher Schultz
Abstract: The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.
Abstract: A topical formulation for transdermal delivery of sub-acute does of doxycycline hyclate to treat pain and inflammation may include: a base suspension; and doxycycline hyclate. The doxycycline hyclate is mixed with the base suspension in a proportion such that the formulation lacks any antibiotic effect and the concentration of doxycycline hyclate is between 200 and 600 mg/g inclusive. A method of applying the formulation is also disclosed.
Abstract: The invention relates to methods for treating chronic liver disease, in particular nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), with neutrophil elastase inhibitors. The invention further relates to pharmaceutical compositions comprising neutrophil elastase inhibitors.
Type:
Grant
Filed:
April 22, 2019
Date of Patent:
October 20, 2020
Assignee:
pH Pharma Co., Ltd.
Inventors:
Sanjeev Satyal, Brian Roberts, Xueyan Wang, Scott Savage, Hoyoung Huh
Abstract: Compositions and methods for inducing PD-L1 internalization are disclosed. The methods include reducing the amount of cell surface PD-L1 by contacting a cell expressing PD-L1 with a compound that binds to cell surface PD-L1 and induces PD-L1 internalization. Compounds that induce PD-L1 internalization can be used to enhance, stimulate and/or increase an immune response and treat a PD-1-related disease or condition.
Abstract: Disclosed herein are compositions comprising benzyl alcohol, one or more cationic antimicrobial agent, and one or more emollient, the combination of which results in persistent antimicrobial activity after application to the skin. The compositions optionally further comprise an organic acid and/or a zinc salt, such as zinc gluconate, as an anti-irritant.
Type:
Grant
Filed:
March 12, 2018
Date of Patent:
October 20, 2020
Assignee:
The Trustees of Columbia University in the City of New York
Inventors:
Shanta M. Modak, Santoshkumar Hanmantrao Dongre
Abstract: Provided are bispecific conjugates having the general formula: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the treatment of cancer.
Type:
Grant
Filed:
August 1, 2018
Date of Patent:
October 13, 2020
Assignee:
Sorrento Therapeutics, Inc.
Inventors:
James T. Patterson, Gunnar F. Kaufmann, Yanwen Fu, Tong Zhu
Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Type:
Grant
Filed:
October 14, 2015
Date of Patent:
September 8, 2020
Assignee:
GW Research Limited
Inventors:
Geoffrey Guy, Stephen Wright, Orrin Devinsky
Abstract: Disclosed are abuse resistant oral pharmaceutical compositions that reduce the likelihood of improper administration of drugs that are susceptible to abuse. The oral pharmaceutical formulations contain abuse deterrent agents that cause discomfort to the user when administered in an improper manner and make the extraction of an active ingredient more difficult. Methods of making and using the compositions are also disclosed.
Type:
Grant
Filed:
December 31, 2014
Date of Patent:
August 18, 2020
Assignee:
KASHIV BIOSCIENCES, LLC
Inventors:
Harpreet Kaur Sandhu, Siva Ram Kiran Vaka, Ashish Chatterji, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
Abstract: The present invention relates to compositions, methods and kits for the treatment of respiratory disease. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of exacerbations of asthma and chronic obstructive pulmonary disease. The present invention provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating or preventing a respiratory disease in a subject. The present invention also provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of ALK5, thereby treating or preventing a respiratory disease in a subject, wherein the inhibitor is administered directly to the airway and/or lungs.
Abstract: Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.
Abstract: Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.
Abstract: Compounds of formula (I) wherein R1, R2, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
Type:
Grant
Filed:
September 21, 2016
Date of Patent:
June 2, 2020
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Daniel Hunziker, Jerome Hert, Holger Kuehne, Patrizio Mattei, Markus Rudolph
Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
Abstract: A method of promoting remyelination in a subject in need thereof includes administering to the subject a therapeutically effective amount of at least one (1,3) Diazole compound, wherein the therapeutically effective amount is the amount effective to induce endogenous oligodendrocyte precursor cell (OPC) differentiation in the subject's central nervous system.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
May 19, 2020
Assignee:
Case Western Reserve University
Inventors:
Paul J. Tesar, Fadi J. Najm, Robert H. Miller
Abstract: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.
Abstract: In certain embodiments the present invention involves methods of killing tumor cells that comprise an oncogenic PDGFR mutation, and methods of treating subjects having tumors that comprise such tumor cells. In some embodiments such methods involve using PI3K inhibitors, or a combination of a PI3K inhibitor and an mTOR inhibitor, or a dual PI3K/mTOR inhibitor. The present invention also provides methods for determining whether a subject is a candidate for treatment, methods for evaluating the efficacy of treatment, and other methods, compositions, model systems, and assays.
Abstract: The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising such compounds, for use for treating and/or preventing endometriosis.